AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling
AEON Biopharma (NASDAQ:AEON) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth